Robert F. Kennedy Jr. is head­ed for Sen­ate con­fir­ma­tion fol­low­ing Tues­day’s com­mit­tee vote and a state­ment of sup­port from the GOP’s biggest skep­tic.

But it’s still very, very un­clear which Kennedy Amer­i­cans are like­ly to end up with — the an­ti-vac­cine cru­sad­er, or a more mod­er­ate ver­sion who made (vague) promis­es last week that he would let in­de­pen­dent sci­ence lead.

In the space of just a few min­utes on Tues­day, that ques­tion got even mud­di­er. Just ahead of the Sen­ate Fi­nance vote, Trump post­ed on so­cial me­dia that “20 years ago, Autism in chil­dren was 1 in 10,000. NOW IT’S 1 in 34. WOW! Some­thing’s re­al­ly wrong. We need BOB­BY!!!”

Pfiz­er's next deals are like­ly to be longer-term ef­forts to re­load its R&D work rather than big-tick­et, late-stage as­sets, the com­pa­ny's top ex­ec­u­tives said Tues­day.

“Look­ing for­ward, we are look­ing at more strate­gic op­por­tu­ni­ties right now, which will en­hance the pipeline in ar­eas that we would like to play, rather than near-term rev­enues,” CEO Al­bert Bourla told in­vestors Tues­day.

The com­pa­ny has about $10 bil­lion to $15 bil­lion it could put to­ward M&A this year, ac­cord­ing to CFO Dave Den­ton. He pre­vi­ous­ly guid­ed that while there’s al­ways “a lit­tle flex­i­bil­i­ty to do BD,” large trans­ac­tions would like­ly be kicked to 2026 or be­yond. Pfiz­er has made de-lev­er­ing a pri­or­i­ty, with bil­lions in cost cuts ini­ti­at­ed and ex­e­cut­ed, and bil­lions more raised by sell­ing off stakes in Ha­le­on, a con­sumer health wing co-run with GSK.

De­spite un­cer­tain­ty around HPV vac­cine sales in Chi­na, Mer­ck CEO Rob Davis said he’s con­fi­dent the com­pa­ny can “de­liv­er strong growth” and nav­i­gate Keytru­da’s im­pend­ing patent cliff.

Davis called the Chi­nese mar­ket chal­lenges a “short-term head­wind” for Mer­ck. Low­er-than-ex­pect­ed de­mand for Gar­dasil led the com­pa­ny to pause ship­ments to Chi­na on Tues­day and drove its stock MRK down 10%. But when it comes to long-term sales ex­pec­ta­tions, Davis said Mer­ck was “nev­er count­ing on Gar­dasil as a growth dri­ver.”

“We al­ways had an ex­pec­ta­tion that even­tu­al­ly it would start to plateau,” he said dur­ing Mer­ck’s fourth-quar­ter earn­ings call on Tues­day. Davis tout­ed high­er de­mand for Gar­dasil out­side of Chi­na, and said “over­all busi­ness is healthy and grow­ing.”

John­son & John­son has asked a fed­er­al dis­trict court to ex­pe­dite its de­ci­sion in a case over the com­pa­ny’s pro­posed 340B re­bate mod­el, cit­ing up­com­ing dead­lines for com­ply­ing with the In­fla­tion Re­duc­tion Ac­t's drug pric­ing pro­vi­sions.

The com­pa­ny has un­til Sept. 1 to sub­mit a writ­ten plan to CMS with its "in­tend­ed pro­ce­dures" for meet­ing its oblig­a­tions un­der the IRA's drug price ne­go­ti­a­tion pro­gram. But J&J said it faces "sig­nif­i­cant ob­sta­cles" to com­ply­ing with a key re­quire­ment: pre­vent­ing du­pli­cate dis­counts un­der the IRA and 340B.

The law­suit stems from the fed­er­al gov­ern­men­t's re­jec­tion of J&J's pro­posed re­bate mod­el, which the com­pa­ny says would help curb du­pli­cate dis­counts and re­duce fraud and abuse with­in the 340B pro­gram. J&J on Mon­day asked the US Dis­trict Court for the Dis­trict of Co­lum­bia for a rul­ing by Ju­ly 1.